BioWorld looks at translational medicine, including: Metabolic changes are antibiotic resistance mechanism; Tumor neoantigens can inhibit immune response; Chromosome organization machinery linked to DNA repair.
Keeping you up to date on recent developments in oncology, including: CD161 identified as impediment to immune response in diffuse glioma; iPSCs give sneak preview of AML; A role for chloroquine in cancer; Fecal transplant may aid in response to immunotherapy in melanoma.
Researchers at Hannover Medical School have developed an organoid that mimicked the early codevelopment of the heart with liver, lung and blood vessels.
Keeping you up to date on recent developments in neurology, including: Understanding ‘brain fog’ in people with COVID-19; AD diagnostics could become more accessible; Careful with that BBB.
As of the end of January, SARS-CoV-2 has demonstrably infected more than 100 million individuals globally. It has killed more than 2 million. And the long-term sequelae of COVID infections – to say nothing of the health consequences of grief, social isolation and widespread economic distress – are still unfolding and will be for years to come.
Keeping you up to date on recent developments in diagnostics, including: Prostate cancer risk scores; Predicting phase separation; iPSCs give sneak preview of AML.
Twenty years to the month after the completion of the draft sequence of the human genome, the Human Genome Project and follow-on projects like The Cancer Genome Atlas are underpinning advances in precision medicine.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
